Phase III Trial Comparing XELOX Regimen (Oxaliplatin Plus Capecitabine) Versus EOX Regimen (Epirubicin, Oxaliplatin and Capecitabine) as First-Line Treatment for Advanced Gastric Cancer: The EXELOX Trial

Xiaodong Zhu(Fudan University Shanghai Cancer Center), Weijian Guo(Shanghai Medical College of Fudan University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuefeng Song(Shanxi Provincial Cancer Hospital), Jun Wu(Kumamoto University), Li‐Xin Qiu(Fudan University Shanghai Cancer Center), Yanru Qin(Zhengzhou University), QinQin Liu(Shanghai Medical College of Fudan University), Jianmei Ji(Nantong Tumor Hospital), Cheng-yan Zhang(Shanxi Provincial Cancer Hospital), Wenhua Li(Shanghai Medical College of Fudan University), Xiaofeng Wang(Zhengzhou University), Qi Wang(Anhui Medical University), Xin Liu(Shanghai Medical College of Fudan University), Xiaowei Zhang(Fudan University Shanghai Cancer Center), Chenchen Wang(Shanghai Medical College of Fudan University), Zhe Zhang, Yusheng Wang(Hunan Agricultural University), Hong Zheng(University of Minnesota), Qi Xu(China Jiliang University), Wanjing Feng(Fudan University Shanghai Cancer Center), Shusheng Wu(University of Science and Technology of China), Lei Yang(Nantong Tumor Hospital), Yifu He(Anhui Provincial Hospital), Zhe Gong(Sir Run Run Shaw Hospital), Jianfeng Luo(Chinese Academy of Medical Sciences & Peking Union Medical College), Mingzhu Huang(Fudan University Shanghai Cancer Center), Jianling Zou(Zhejiang Cancer Hospital), Jian Zhao(Dana-Farber Cancer Institute), Zhiyu Chen(Chongqing University), JieYun Zhang(Shanghai Medical College of Fudan University), Wen Zhang(Shanghai Medical College of Fudan University), Xiaoying Zhao(Shanghai Medical College of Fudan University)
SSRN Electronic Journal
January 1, 2021
Cited by 1


Related Papers